ReviewAmerican journal of therapeutics2017
Potential Clinical and Economic Impact of Switching Branded Medications to Generics.
Review in American journal of therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Drug Brand Switching: A Regulatory Perspective.Drug safety · 2026Review
- Regional variation and trends in prostaglandin analogue prescribing for glaucoma in England 2019-2024.Eye (London, England) · 2026Article
- Economic evaluation of generic inhalational bronchodilators from the Jan-Aushadi scheme versus branded alternatives.Cost effectiveness and resource allocation : C/E · 2025Article
- Article
- Evaluating the understanding and perception of final-year pharmacy and medical students regarding generic medicines: a cross-sectional study in Abbottabad, Pakistan.BMC medical education · 2025Article
- Testing the unintended cost effects of health policies for generic substitutions: the case of China's National Volume-Based Procurement (NVBP) policy.Health policy and planning · 2025Article
- Breaking barriers: how generic drugs democratize mental health.Frontiers in pharmacology · 2025Article
- International comparison of generic competition, prices, and usage trends: South Korea and G20 countries.Frontiers in public health · 2025Article
- Implementation status and challenges affecting antimicrobial stewardship programmes in private hospitals in Kampala, Uganda: Insights from a cross-sectional descriptive survey.PLOS global public health · 2025Article
- Antimicrobial drug pricing.Communications medicine · 2024Article
- Tolerability and Acceptance of Switching from Brand to Generic Glatiramer Acetate in Multiple Sclerosis.Journal of clinical medicine · 2024Article
- Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspects.BMC medical research methodology · 2024Article
- Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia's perspective.Frontiers in pharmacology · 2024Article
- Article
- Opinion of Polish Patients with Epilepsy on Generic Medications.Healthcare (Basel, Switzerland) · 2023Article
- The clinical and Practice Dilemma of Frequent Switching Among Generic Medications: Magnitude and Patient Safety Prospective.Hospital pharmacy · 2023Article
- A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia.Drugs - real world outcomes · 2023Article
- Does China's competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine.Frontiers in pharmacology · 2023Article
- Patients' Experience of Medication Brand Changes during Hormone Therapy for Breast Cancer-An Interpretative Phenomenological Analysis.Healthcare (Basel, Switzerland) · 2022Article
- Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Switching branded to generic medications has become a common cost-containment measure. Although this is an important objective for health care systems worldwide, the impact of this practice on patient outcomes needs to be carefully considered. We reviewed the literature summarizing the potential clinical and economic consequences of switching from branded to generic medications on patient outcomes. A literature search of peer-reviewed articles published 2003-2013 using key words of "generic switching" or "substitution" was conducted using PubMed, OvidSP, and ScienceDirect. Of 30 articles identified and reviewed, most were related to the diseases of the central nervous system, especially epilepsy. Based on our review, potential impacts of switching fell into 3 broad categories: patient attitudes and adherence, clinical and safety outcomes, and cost and resource utilization. Although in many cases generics may represent an appropriate alternative to branded products, this may not always be the case. Specifically, several studies suggested that switching may negatively impact medication adherence, whereas other studies found that generic switching was associated with poorer clinical outcomes and more adverse events. In some instances, switching accomplished cost savings but did so at increased total cost of care because of increased physician visits or hospitalizations. Although in many cases generics may represent an appropriate alternative, mandatory generic switching may lead to unintended consequences, especially in certain therapeutic areas. Although further study is warranted, based on our review, it may be medically justifiable for physicians and patients to retain the right to request the branded product in certain cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.